ArticleAging2024
On standardization of controls in lifespan studies.
Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- IRAP deficiency preserves renal function and attenuates pathology in aged mice.Clinical science (London, England : 1979) · 2026Article
- Multitissue, multi-time point transcriptomic atlas of aging in mice and rats.Science advances · 2026Article
- Biomarkers of aging: from molecules and surrogates to physiology and function.Physiological reviews · 2025Review
- Article
- The impact of co-housing on murine aging studies.GeroScience · 2025Article
- Compression of morbidity by interventions that steepen the survival curve.Nature communications · 2025Article
- Short lifespan is one's fate, long lifespan is one's achievement: lessons from Daphnia.GeroScience · 2024Article
- BayesAge 2.0: A Maximum Likelihood Algorithm to Predict Transcriptomic Age.bioRxiv : the preprint server for biology · 2024Article
- Quantifying the Impact of Co-Housing on Murine Aging Studies.bioRxiv : the preprint server for biology · 2024Article
- Advancing longevity research through decentralized science.Frontiers in aging · 2024Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
The search for interventions to slow down and even reverse aging is a burgeoning field. The literature cites hundreds of supposedly beneficial pharmacological and genetic interventions in model organisms: mice, rats, flies and worms, where research into physiology is routinely accompanied by lifespan data. However, when experimental animals from one article live as long as controls from another article, comparing the results of interventions across studies can yield misleading outcomes. Theoretically, all lifespan data are ripe for re-analysis: we could contrast the molecular targets and pathways across studies and help focus the further search for interventions. Alas, the results of most longevity studies are difficult to compare. This is in part because there are no clear, universally accepted standards for conducting such experiments or even for reporting such data. The situation is worsened by the fact that the authors often do not describe experimental conditions completely. As a result, works on longevity make up a set of precedents, each of which might be interesting in its own right, yet incoherent and incomparable at least for the reason that in a general context, it may indicate, for example, not prolonging the life of an average organism, but compensating for any genetic abnormalities of a particular sample or inappropriate living conditions. Here we point out specific issues and propose solutions for quality control by checking both inter- and intra-study consistency of lifespan data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.